PFE Pfizer GOING LOWERFrom the chart, there are 2 things that concern me :
1 - The bearish cross on the CMF (Chaikin Money Flow Indicator)
Chaikin Money Flow (CMF) is a technical analysis indicator used to measure Money Flow Volume over a set period of time. Money Flow Volume is a metric used to measure the buying and selling pressure of a security for single period. CMF then sums Money Flow Volume over a user defined look-back period. Chaikin Money Flow's Value fluctuates between 1 and -1. CMF can be used as a way to further quantify changes in buying and selling pressure and can help to anticipate future changes and therefore trading opportunities.
2 - The market gaps
There is still a gap at $34 and market gaps are usually filled. Not even to mention the huge gap that had just occurred after the news of a successful vaccine candidate.
PFE has exhibited high volatility during the past few months and each high is always followed by a huge sell of. It's like PFE just can't get ahead.
That being said, if you're looking to buy PFE (because viagra isn't going anywhere), I'd be counting on the market gap at $34 as an entry point.
Please support me by hitting like,
wishing you successful trading!
Best Regards,
Ev
PFIZER
The Pfizer News: Hear it First!Stocks have blasted through new highs completely disregarding election drama and focusing solely on the Pfizer news. Indeed news of a 90% success rate in the vaccine has fueled a risk on frenzy. It is really difficult to "crystal ball" what's going to happen other than to say that a retracement is likely at some point. This news seems highly dubious and when that is priced into the markets we could retrace the entire move and then some. I'd be highly skeptical of this move. That being said, I would also not get in the way of this freight train. If you have an existing stock portfolio you should be singing right now. But I would also consider taking profits. We have just found resistance at a Fibonacci Extension level, which may prove to be a retracement. The Kovach OBV is incredibly bullish so there is a lot of meat to this rally.
PFE - buy support zones analysisHello traders,
Description of the analysis:
PFIZER ( PFE ) support zones ideal for timing long positions (gray). Trade what you understand, trade carefully and sparingly according to the business plan.
About me:
Hi, my name is Jacob Kovarik and I´m trading on stock exchange since 2008. I started with a capital of 3000 USD. My first strategy was based on OTM options. (American stock index and their ETF ). I´ve learnt on my path that professional trading is based on two main fundaments which have to complement each other, to make a bussiness attitude profitable. I´ve tried a lot of techniques and many manners how to analyze the market. From basic technical analysis to fundamental analysis of single title. My analytics gradually changed into professional attitude. I work with logical advantages of stock exchange (return of value back to average, volume , expected volatility , advantage of high stop-loss, the breakdown of time in options, statistics and cosistent thorough control of risk). At the moment, my main target is ITM on SPM index. Biggest part of my current bussiness activity comes from e mini futures (NQ, ES). I´m trader of positions. I´m from Czech republic and I take care of a private fund (over $4.000.000 USD). During my career I´ve earned a lot of valuable experience, such as functionality of strategies and what is more important, control of emotions. Professional trading is, in my opinion, certain kind of mental training and if we are able to control our emotions, accomplishment will show up. I will share with you my analysis and trades on my profile. I wish to all of you successul trades.
Jacob
Pfizer: Strong Sell Opportunity.PFE continues to underperform on the long-term and under the recent fundamentals the pressure on it is growing. The Bearish Megaphone on 1D (RSI = 33.977, MACD = -1.120, ADX = 56.370) has printed a bearish continuation sequence that extends at least towards the 27.90 Support.
** If you like our free content follow our profile to get more daily ideas. **
Comments and likes are greatly appreciated.
Up..Up..& Away! Priority Review for Cancer DrugAt 8:30 AM NEWS
This morning Myovant Sciences announced priority review for Relugolix for Advanced Prostate Cancer.
The stock should have been up a lot more than what it was on the news but due to the non-circulation of the release, the stock did not move much.
Today at 4:05 PM, after the market closed, the stock started moving higher on more positive news.
At 4:05 PM NEWS
Myovant Sciences to Host Webcast and Conference Call at 8:30 AM EST on June 23, (Tomorrow Morning), to discuss results for Phase 3 SPIRIT 1 Study Evaluating Once-Daily Reglugolix Combination Therapy in Women with Endometriosis.
This company has a lot of positive things moving forward including...
On 6/11/2020, the stock got a boost with a price target of $45.00 a share.
Daily Chart looks good with indicators turning up, Bullish
Weekly Chart also looks Bullish
Long!
DISCLAIMER
The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
PFIZER SHORT Trading PlanEU states back spending up to $2.7 billion upfront on COVID-19 vaccines however,EU officials said the bloc would not buy vaccines produced exclusively in the United States, which includes PFIZER, fearing that would delay supplies to Europe.
Hence, I expect the share price will dip further.
Key Trading Plan:
i) SHORT when it reaches the pull back price at 34.98 and it breaks support level at 32.87 before reaching target Take Profit point at 28.28.
ii) LONG when the price breaks the resistance level of 36.89 with the target Take Profit point at 39.33
Author:
S.I.D. Aizu
Pfizer: PFE. Hardly any downside. Perfect Entry.The bad news with Pfizer's clinical trial is great news for traders and investors.
Why? Because the 'bottom' has been gauged by this piece of over the weekend news.
The bad news does not materially affect existing revenue stream and earnings.
The lack of movement intraday suggests that institutions have completely priced in the negative effect of the news before market open.
Anyone who wanted and NEEDED to sell has mostly sold, and there was no lack of buyers to take those orders at the $35.50.
Perfect opportunity for a long trade, short term or long.
Anything above 34.50 is a BUY.
Interval Targets are the Fibonacci levels on the chart. Final target: $45






















